FOSTER CITY, CA--(Marketwire - September 04, 2009) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at the Rodman & Renshaw Annual Global Investment Conference in New York City. Friedhelm Blobel, Ph.D., SciClone's President and Chief Executive Officer, will present a corporate overview and business update on Thursday, September 10, 2009 at 10:50 am ET.
To access the live audio webcast of the presentation, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com.
About SciClone
SciClone Pharmaceuticals (NASDAQ: SCLN) is a profit-driven, global
biopharmaceutical company with a substantial international business and a
product portfolio of novel therapies for cancer and infectious diseases.
SciClone is focused on continuing international sales growth, a
cost-containing clinical development strategy, and expense management.
ZADAXIN (thymalfasin or thymosin alpha 1) is sold in over 30 countries for
the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers
and as a vaccine adjuvant. SciClone's pipeline of drug candidates includes
thymalfasin for stage IV melanoma, for which SciClone has reached agreement
with the FDA on the design of a phase 3 trial; RP101 in a phase 2 trial for
the treatment of pancreatic cancer; SCV-07 in a phase 2 trial for the delay
of onset of severe oral mucositis in patients receiving chemoradiation
therapy for the treatment of cancers of the head and neck; and SCV-07 with
a ready-to-initiate phase 2 trial for the treatment of HCV. SciClone has
exclusive commercialization and distribution rights to DC Bead™ in China,
where the product is under regulatory review. The Company also has
commercialization and distribution rights to an anti-nausea drug
ondansetron RapidFilm™ in China and Vietnam, for which it is seeking
regulatory approval. For additional information, please visit
www.sciclone.com.
